LOGO
LOGO

TODAY'S TOP STORIES

Biotech Stocks Of 2022 Which Delivered Double-digit Gains

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
rttnewslogo20mar2024

Biotech stocks are fraught with high risk, but they also present high-reward opportunities for investors.

Let's take a look at some of the healthcare stocks that delivered double-digit returns since our reporting.

Want to know more about biotech stocks with high gains? Why not take a look at "52 Biotech Stocks Of 2022 With Triple-Digit Gains"?

Headlines

Published Date

Published Price

Maximum Price Since Publishing

Last Closing Price

Max Gain %

GOSS - Gossamer Bio Rallies On $120 Mln Investment By Institutional Investors

Jul. 13

$7.62

$15.20

$2.73

99.48%

APEN - Premarket Mover: Apollo Gains Weight On De Novo Marketing Authorization For Certain Devices

Jul. 13

$5.17

$10.30

$9.97

99.23%

VIGL - Why Vigil Neuroscience Is Turning Heads

Sep. 22

$8.50

$16.77

$12.54

97.29%

BCLI - Brainstorm Plunges As FDA Refuses To Review ALS Treatment

Nov. 10

$1.20

$2.33

$1.92

94.17%

DCPH - Deciphering DCPH...

Apr. 26

$10.83

$20.88

$15.31

92.80%

SRTS - Sensus Healthcare Delivers Strong Q1 Results

May. 6

$7.92

$15.25

$6.42

92.55%

APEN - Apollo Endosurgery To Report Q2 Results On Aug.2

Jul. 25

$5.36

$10.30

$9.97

92.16%

VACC - Vaccitech To Report Additional Interim Efficacy Data On VTP-300 In Chronic HBV Infection Next Month

May. 16

$3.91

$7.45

$2.29

90.54%

KPTI - Will The Momentum Continue In Karyopharm?

Jan. 11

$7.75

$14.73

$3.10

90.06%

CLPT - ClearPoint Makes It Clear - Revenue And Footprint To Expand

Feb. 16

$8.93

$16.96

$8.40

89.92%

DAWN - Day One Skyrockets On Positive Study Results Of Tovorafenib In Pediatric Brain Tumor

Jun. 13

$14.94

$28.35

$21.42

89.76%

TRVI - Trevi Therapeutics' PRISM Trial Of Haduvio In Prurigo Nodularis Meets Goals

Jun. 29

$2.47

$4.68

$2.11

89.47%

ABCL - AbCellera Biologics - Waiting For Its Heyday…

May. 18

$7.92

$14.97

$10.21

89.02%

RLMD - Relmada's REL-1017 Demonstrates Lack Of Abuse Potential In Second Study Too

Feb. 23

$20.50

$38.68

$3.37

88.68%

ISEE - IVERIC's Phase III Geographic Atrophy Trial Meets Goal, Shares Jump

Sep. 6

$12.96

$24.33

$22.32

87.73%

RVPH - Reviva - Waiting To RECOVER

Oct. 12

$3.25

$6.10

$3.75

87.69%

SIGA - SIGA Technologies Rallies As WHO Declares Monkeypox A Global Health Emergency

Jul. 25

$14.45

$26.99

$7.64

86.78%

AGIO - Will Agios' Pyrukynd Secure Blockbuster Tag?

Jun. 23

$18.72

$34.76

$29.71

85.68%

ESPR - Will Esperion's Q1 Results Beat Estimates?

Apr. 21

$4.80

$8.87

$6.14

84.79%

BVNKF - Bavarian Back In Focus As Monkeypox Cases Rise

May. 20

$31.57

$58.02

$30.90

83.78%

OCUL - Ocular Therapeutix Q1 Results - Hit Or Miss?

May. 2

$3.57

$6.53

$2.73

82.91%

ACCD - Accolade's Revenue For Q2 Of Fiscal 2023 To Grow 12% To 14%

Jul. 1

$7.55

$13.80

$8.46

82.78%

LABP - Landos - Bracing For A Busy Quarter Ahead

Jul. 1

$0.75

$1.37

$0.26

82.67%

TCRT - Alaunos To Make Presentations At The International Cancer Immunotherapy Conference

Aug. 25

$2.20

$4.01

$0.59

82.27%

ZYXI - Zynex: What's Making News?

Jun. 13

$7.99

$14.55

$13.32

82.10%

MCRB - When Will Microbiome Therapy Join The Recurrent C.diff Infection Armamentarium?

Sep. 2

$5.22

$9.49

$5.75

81.80%

OLK - Exploring Olink...

Jan. 21

$13.76

$24.93

$23.00

81.18%

ZLAB - Zai Lab Q1 Revenue Jumps More Than Twofold

May. 11

$30.00

$53.95

$32.59

79.83%

MDGL - Madrigal Pharma Reports Encouraging Data From NASH Trial; Shares Gain 15%

Jan. 31

$59.20

$105.93

$63.80

78.94%

BNR - Will Burning Rock Regain Ground?

Jun. 1

$2.40

$4.24

$2.55

76.67%

MASS - 908 Devices Sees Revenue Growing At 23-30% In FY22

Jun. 6

$14.76

$26.00

$8.49

76.15%

AMLX - Amylyx Pharma Ascends 16%

Jul. 5

$22.63

$39.78

$35.67

75.78%

ALDX - Aldeyra's Crossover Trial Of Dry Eye Disease Drug Achieves Goals; Stock Up Over 15%

Jul. 12

$4.55

$7.99

$6.32

75.60%

XAIR - Beyond Air Breathes Easy

Jun. 29

$6.70

$11.76

$6.17

75.52%

VERU - Veru Rises 17% On Submission Of EUA Application For Its Covid-19 Treatment

Jun. 7

$14.00

$24.55

$4.99

75.36%

CGEM - Cullinan Oncology Soars On Deal With Taiho Pharma

May. 12

$9.08

$15.89

$11.44

75.00%

PSTX - Poseida Inks Blockbuster Strategic Global Collaboration Agreement With Roche

Aug. 3

$3.68

$6.43

$0.81

74.73%

CANO - Cano Aiming For 75%-81% Revenue Growth In FY22

Jul. 7

$5.59

$9.75

$1.21

74.42%

KNSA - Kiniksa To Report Prurigo Nodularis Trial Data In 2H 2022

Jun. 22

$9.88

$17.20

$15.87

74.09%

PEAR - Will Pear Bloom?

Jan. 31

$3.92

$6.74

$1.62

71.94%

TXMD - TherapeuticsMD Jumps On Receiving Equity Investment From Rubric Capital

Aug. 1

$6.81

$11.69

$7.09

71.66%

CUE - Cue Biopharma Rallies On Getting Fast Track Designation For Its Head And Neck Cancer Drug Candidate

Oct. 4

$2.45

$4.19

$2.70

71.02%

APLT - Applied Therapeutics To Present AT-007 Data At The Annual Clinical Genetics Meeting

Mar. 17

$1.60

$2.73

$0.76

70.63%

RPTX - Repare Therapeutics Rallies In Pre-market On Collaboration With Roche For Camonsertib

Jun. 2

$10.97

$18.68

$15.34

70.28%

AHCO - AdaptHealth Looks Good, Can It Make You Rich?

Apr. 13

$16.20

$27.48

$19.75

69.63%

GH - Guardant Health's Revenue To Grow By 23% To 26% In 2022

May. 24

$37.00

$62.75

$30.06

69.59%

PTCT - PTC Therapeutics' Upstaza Just One Step Away From Getting Approval In Europe

May. 20

$32.83

$55.58

$39.22

69.30%

STRO - Sutro Soars On Deal With Astellas To Advance Novel Immunostimulatory Antibody-drug Conjugates

Jun. 28

$4.98

$8.37

$7.30

68.07%

VIRX - Viracta Therapeutics Anticipates Data From Nana-val Trial In 2H 2022

Jun. 30

$3.43

$5.75

$1.78

67.64%

ASRT - Assertio Expects 2022 Product Sales To Grow 16% To 24%

Mar. 28

$2.65

$4.44

$3.66

67.55%

FIXX - FDA Lifts Clinical Hold On Homology Medicines' Phenylketonuria Gene Therapy Trial

Jun. 14

$1.97

$3.30

$1.37

67.51%

TSHA - Taysha Gene Awaits Regulatory Feedback For Gene Therapy TSHA-120

Jun. 7

$3.07

$5.09

65.80%

MYNZ - Mainz Acquires Rights To Biomarkers With Potential To Enhance ColoAlert's Utility; Stock Rises

Jan. 5

$18.21

$30.00

$1.08

64.74%

AURA - Throwing Light On Aura...

Jul. 8

$15.08

$24.83

$12.17

64.66%

DH - Definitive Healthcare Foresees 33% To 35% Revenue Growth In 2022

May. 27

$18.31

$30.11

$2.14

64.45%

MYOV - Myovant Sciences Gets Expanded FDA Approval For Myfembree; Stock Up

Aug. 8

$16.41

$26.93

$26.89

64.11%

PLRX - Premarket Mover: Pliant Therapeutics Soars On INTEGRIS-IPF Study Data

Jul. 11

$16.01

$26.25

$18.69

63.96%

ARDX - Will Ardelyx' Xphozah Make It To The Finish Line?

Oct. 13

$1.34

$2.19

$1.96

63.43%

HAE - Haemonetics Adds 15% On Reporting Q4 Profit, Beating Estimates

May. 10

$53.00

$86.58

$78.33

63.36%

RCKT - Rocket Pharma - Yet To Take Off...

Sep. 14

$14.11

$22.89

$22.24

62.23%

AUVI - Applied UV Soars As Its Distributor Gets Exclusive Deal In Pakistan

Jun. 9

$2.60

$4.20

$1.08

61.54%

ATHX - Athersys To Provide Update On Clinical Programs On Feb.2

Jan. 27

$20.75

$33.25

$3.16

60.24%

BMEA - Biomea Fusion - What's In Store For 2022?

Jan. 4

$8.89

$14.20

$8.06

59.73%

DYN - Dyne Gearing Up For Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 Trials

Jul. 14

$9.79

$15.63

$13.52

59.65%

AXNX - Axonics On Track To Post Over 30% Revenue Growth In 2022

May. 26

$50.13

$79.92

$59.81

59.43%

RAD - Rite Aid Corp. Climbs 8% After Raising Annual Revenue Outlook Above Estimates

Jun. 23

$7.29

$11.61

$4.27

59.26%

BTTX - Will BTTX See Better Days Ahead?

Apr. 5

$2.05

$3.23

$1.49

57.56%

TCDA - Will Veverimer Take The Crown As 1st Therapy To Treat Metabolic Acidosis And Slow CKD Progression?

Jun. 15

$8.80

$13.85

$0.17

57.39%

SGFY - Signify Health Sees Significant Momentum Heading Into H2

Aug. 5

$19.00

$29.88

$28.54

57.26%

MRUS - Will Merus Get A Boost From ENRGy Trial Data?

May. 31

$19.62

$30.81

$13.21

57.03%

OKYO - What's Making News At OKYO Pharma?

May. 25

$2.20

$3.45

$2.26

56.82%

SNDX - Syndax Pharma - For The Long Haul

Mar. 2

$16.95

$26.51

$24.42

56.40%

CTIC - What's Making News At CTI BioPharma?

Apr. 6

$4.99

$7.80

$5.71

56.31%

DCGO - A Quick Look At DocGo...

Feb. 10

$7.30

$11.41

$6.94

56.30%

AXSM - Axsome Rises As Investors Cheer FDA Approval Of Major Depressive Disorder Drug

Aug. 19

$51.89

$80.87

$78.40

55.85%

DSGN - Is DT-216 Well-designed?

Jul. 14

$16.89

$26.30

$8.76

55.71%

ESPR - Esperion - Waiting For A Clear Outcome

Jun. 21

$5.70

$8.87

$6.14

55.61%

NVNO - A Quick Look At EnVVeno Medical...

Jul. 12

$5.10

$7.93

$5.23

55.49%

ASND - Will Ascendis Make An Ascent?

Jun. 23

$86.55

$134.52

$118.60

55.42%

CRIS - Curis Rises On TakeAim Lymphoma, TakeAim Leukemia Data Presentation

Jun. 6

$1.14

$1.77

$0.50

55.26%

INMD - InMode Up 12% As Prel. Results Come In Above Street View; Ups Guidance

Jul. 12

$25.99

$40.29

$36.33

55.02%

PRAX - Praxis Precision To Report Aria Study Data In June

May. 12

$8.60

$13.33

$2.28

55.00%

PRAX - Praxis At New Low As Study Of Its PRAX-114 For MDD Does Not Achieve Primary Goal

Jun. 6

$3.16

$4.89

$2.28

54.75%

NTRA - Natera Expects 23% To 26% Revenue Growth In 2022

Apr. 19

$37.50

$57.88

$43.32

54.35%

PRCT - What's Driving PROCEPT BioRobotics' Revenue?

Jun. 27

$34.00

$52.40

$43.00

54.12%

AMEH - Apollo Medical Expects FY2022 Revenue To Grow 36% To 40%

Jun. 3

$37.69

$58.00

$31.14

53.89%

CUTR - Cutera Up On FDA Approval Of Its AviClear Acne Treatment Device

Mar. 25

$48.41

$74.38

$45.57

53.65%

AKYA - Akoya Biosciences To Report Q4 Results On Mar.14

Mar. 11

$10.79

$16.57

$12.22

53.57%

TCDA - Will Tricida Prove Its VALOR?

Sep. 23

$8.60

$13.12

$0.17

52.56%

OM - At The Outset...

Jul. 25

$17.42

$26.48

$25.25

52.01%

RNAZ - TransCode To Advance Lead Candidate Into Clinical Trial In 2H 2022

Feb. 14

$2.03

$3.08

$0.43

51.72%

ALPN - Alpine Immune's Phase I NEON-2 Trial Placed On Partial Clinical Hold

Mar. 7

$6.81

$10.30

$6.82

51.25%

ALBO - Will Albireo Pharma Assert Its Position In Rare Liver Disease Drug Market?

Jan. 6

$24.91

$37.63

$20.29

51.06%

ADPT - Adaptive Biotechnologies Expects Nearly 20% To 26% Revenue Growth In FY22

Jun. 27

$8.75

$13.21

$8.01

50.97%

DRIO - What's Making News At DarioHealth?

Apr. 28

$5.11

$7.69

$3.98

50.49%

AGL - Why Agilon Health Is Worth A Look?

Jun. 13

$18.85

$28.36

$17.23

50.45%

MPLN - MultiPlan Sees 4% To 10% Revenue Growth In 2022

May. 12

$4.12

$6.19

$1.57

50.24%

EIGR - Eiger BioPharmaceuticals Soars On Positive Study Results From Its Covid-19 Treatment

Mar. 17

$6.67

$10.02

$1.12

50.22%

NKTX - Nkarta To Report Additional Data For Two Engineered Natural Killer Cell Programs In 2H 2022

Jun. 21

$12.31

$18.48

$7.03

50.12%

PYPD - Will PolyPid's SHIELDs Make A Mark?

Mar. 15

$4.60

$6.90

$0.75

50.00%

LFMD - LifeMD Revenue Grows 60% In Q1

May. 16

$2.15

$3.22

$2.27

49.77%

HARP - Harpoon To Report Phase I Data Of HPN328 In June

May. 13

$1.93

$2.89

$0.68

49.74%

EXAS - Exact Sciences - On An Accelerated Path To Profitability?

Nov. 7

$37.80

$56.52

$51.92

49.52%

ZYME - Zymeworks Inks Deal With Jazz As It Gears Up For Phase 3 Biliary Tract Cancer Trial Data

Oct. 19

$5.88

$8.73

#N/A

48.47%

EQRX - What's The Buzz At EQRx?

May. 16

$4.08

$6.05

$2.18

48.28%

BTTX - Will BTTX See Better Days Ahead?

Feb. 4

$3.44

$5.10

$1.49

48.26%

TMCI - Treace Medical - Working Towards Establishing Lapiplasty As Standard Of Care For Bunion Treatment

Jul. 28

$16.90

$25.02

$22.95

48.05%

KMPH - KemPharm To Report Cardiovascular Safety Trial Data Of SDX In Q3

Apr. 25

$4.70

$6.92

$4.51

47.23%

REVB - Revelation Bio Bracing For A Busy Year?

Feb. 23

$1.96

$2.88

$0.21

46.94%

QDEL - QuidelOrtho Q3 Revenue To Beat Wall Street Estimates

Oct. 13

$69.80

$102.00

$82.59

46.13%

PDSB - HUTCHMED's Gastric Cancer Trial Meets One Of The Two Primary Endpoints

Nov. 14

$6.90

$10.06

$9.34

45.80%

ABIO - ARCA Biopharma Plunges As COVID-19 Trial Fails To Meet Primary Goal

Apr. 1

$1.78

$2.59

$2.43

45.51%

PODD - Insulet Gets FDA Nod For Omnipod 5, The World's First Tubeless Automated Insulin Delivery System

Jan. 28

$220.00

$320.00

$298.99

45.45%

PRTK - Paratek Sees Demand Trends For Lead Drug NUZYRA To Continue

Aug. 4

$2.52

$3.65

$1.78

44.84%

NOVN - Novan To File For Approval Of Molluscum Contagiosum Treatment In Q4

Jun. 16

$2.30

$3.33

$1.26

44.78%

SLGL - Sol-Gel Awaits Facelift

Jul. 15

$4.76

$6.89

$4.56

44.75%

OLMA - Olema To Present At The 34th EORTC-NCI-AACR Symposium

Oct. 13

$2.85

$4.11

$2.33

44.21%

TXMD - TherapeuticsMD To Divest VitaCare To GoodRx

Mar. 7

$16.07

$23.00

$7.09

43.12%

SMTI - Sanara MedTech - Gaining Traction

Aug. 17

$28.00

$39.99

$39.10

42.82%

CTKB - Cytek Biosciences Expects FY22 Revenue To Grow 25%-31%

Jul. 13

$11.26

$16.05

$10.49

42.54%

VOR - Vor Bio To Report Acute Myeloid Leukemia Trial Data In 2H22

Jun. 13

$5.32

$7.57

$7.07

42.29%

TCMD - Tactile Systems Expects Revenue To Grow 13-15% In 2022

Feb. 24

$15.21

$21.62

$11.46

42.14%

VRDN - Viridian Catches Eyes

Aug. 15

$20.01

$27.95

$27.88

39.68%

GMDA - What's On Tap For Gamida This Year?

Jan. 27

$3.38

$4.72

$1.22

39.64%

CLVS - Clovis Oncology Soars On Positive Data From Monotherapy Arm Of ATHENA Trial

Mar. 31

$2.33

$3.25

$0.08

39.48%

AUGX - Augmedix Expects Revenue Growth Of 43% To 44% In Q4

Feb. 2

$2.42

$3.37

$1.15

39.26%

MRSN - Mersana Inks Option Agreement With GSK For Antibody-drug Conjugate XMT-2056; Stock Up

Aug. 9

$6.00

$8.34

$6.51

39.00%

CERT - A Second Look At Certara

Nov. 8

$13.30

$18.47

$16.17

38.87%

AMLX - Amylyx Pharma Gearing Up For FDA Decision

Sep. 27

$28.68

$39.78

$35.67

38.70%

ATXS - Astria Shines...

Sep. 6

$9.31

$12.86

$11.81

38.13%

APYX - Premarket Mover: Apyx Medical Gets FDA Clearance For Renuvion APR Handpiece

Jul. 18

$8.12

$11.16

$2.00

37.44%

AMYT - Will Amryt Pharma's Q4 Results Lag Or Trump Estimates?

Mar. 8

$6.50

$8.90

$7.03

36.92%

CDMO - Avid's Fiscal 2023 Revenue Expected To Increase 17% To 21%

Jun. 30

$15.00

$20.47

$13.83

36.47%

MYNZ - Mainz Commences International Study Of ColoAlert, Results Expected By Early 2023

Feb. 4

$13.67

$18.63

$7.08

36.28%

SLP - Simulations Plus To Report Q3 Financial Results On July 6

Jul. 4

$49.65

$67.59

$37.96

36.13%

HCA - HCA Healthcare Drops 8% On Lower Quarterly Profit, Revenue

Oct. 21

$183.58

$249.00

$239.05

35.64%

YMAB - Will Y-mAbs' Second Rare Disease Product Get FDA Nod?

Jul. 5

$15.10

$20.48

$5.00

35.63%

PCVX - Vaxcyte Rallies On Pneumococcal Conjugate Vaccine Trial Results

Oct. 24

$35.15

$47.67

$45.80

35.62%

VKTX - Viking Therapeutics To Resume Phase Ib Trial Of VK0214 In X-ALD As FDA Lifts Clinical Hold

Jul. 19

$3.45

$4.65

$4.02

34.78%

ARGX - Argenx' Phase 3 ADAPT-SC Trial In Generalized Myasthenia Gravis Hits Goals

Mar. 22

$302.91

$407.93

$385.81

34.67%

BLPH - How Soon Can Bellerophon REBUILD Itself?

Jul. 18

$1.29

$1.73

$0.77

34.11%

TPST - What's Brewing In Tempest?

May. 9

$3.10

$4.15

$1.36

33.87%

BIOL - Will BIOLASE Bring The Smile Back On Investors' Face?

Jun. 27

$4.44

$5.94

$0.62

33.78%

ZNTL - Zentalis Secures $25Mln Equity Investment

Apr. 27

$24.31

$32.34

$19.81

33.03%

HARP - Harpoon Therapeutics: HPN217 Receives FDA Fast Track Designation

Mar. 2

$4.10

$5.45

$0.68

32.93%

IMPL - NeuroMetrix Soars On Receipt Of Breakthrough Designation From FDA For Quell Technology

Jan. 19

$8.10

$10.75

$3.60

32.72%

BMRA - Biomerica's H. Pylori Antigen Test Awaits FDA Word

Oct. 3

$3.96

$5.25

$3.49

32.58%

LVTX - Lava Therapeutics To Present At J.P. Morgan Healthcare Conference Today

Jan. 12

$5.58

$7.38

$3.65

32.26%

ALT - Altimmune Gears Up For NAFLD Trial Results

Aug. 17

$17.87

$23.49

$11.48

31.45%

XERS - Xeris To Report Q1 Results Tomorrow

May. 10

$1.88

$2.47

$1.29

31.38%

PRVB - MacroGenics Soars On Milestone Payment From Provention Bio For FDA Approval Of Teplizumab

Nov. 18

$7.50

$9.85

$9.28

31.33%

IRIX - For Your Eyes Only...

Jul. 1

$2.66

$3.49

$2.23

31.20%

CMAX - Care To Take A Look At CareMax?

Jul. 26

$6.48

$8.47

$3.13

30.71%

XGN - Will Exagen's Q2 Results Trump Or Miss Estimates

Jul. 11

$6.87

$8.96

$2.47

30.42%

AVXL - Anavex Life Clawing Back Yesterday's Loss?

Feb. 2

$11.69

$15.24

$8.64

30.37%

ELDN - Eledon Pharma To Report ALS Trial Data In June

May. 19

$3.04

$3.95

$2.49

29.93%

SAGE - Sage Therapeutics To Present LUMINARY Study Results Of SAGE-718 In Alzheimer's On Apr.5

Apr. 1

$33.98

$44.07

$40.26

29.69%

HCAT - What's The Next Catalyst For HCAT?

Jun. 2

$14.12

$18.30

$10.79

29.60%

MXCT - MaxCyte - Encouraged By Ongoing Growth Of SPL Portfolio

Sep. 28

$5.82

$7.50

$5.34

28.87%

ATEC - Alphatec - Gaining A Footing?

Feb. 17

$10.62

$13.65

$10.71

28.53%

PGNY - Premarket Mover: Progyny Soars On Upbeat Revenue, Outlook

Aug. 5

$36.20

$46.50

$31.83

28.45%

EXEL - Will Exelixis Excel Or Flunk This Year?

Jan. 18

$18.24

$23.40

$15.94

28.29%

NKTR - Nektar Therapeutics Plunges On Disappointing Melanoma Trial Results

Mar. 14

$5.00

$6.40

$2.66

28.00%

AKYA - Is Akoya Biosciences A Good Bet?

Jul. 5

$12.95

$16.57

$12.22

27.95%

MXCT - Time To Set Sight On MaxCyte?

Feb. 4

$6.07

$7.76

$5.34

27.84%

STVN - Stevanato Expects Nearly 11-12% Revenue Growth In FY22

Jun. 22

$15.19

$19.41

$17.50

27.78%

CODX - Will Co-Diagnostics' Monkeypox PCR Test Pay Off?

Jul. 1

$5.58

$7.13

$2.53

27.78%

BLFS - BioLife Sees Growth In Biostorage Services Platform In 2022 And Beyond

Mar. 15

$21.11

$26.96

$17.58

27.71%

MDGL - Madrigal - Gearing Up For MAESTRO-NASH Data

Sep. 26

$64.99

$83.00

$63.80

27.71%

BTAI - Will Sales Of BioXcel's Agitation Drug Make A Splash?

Jul. 11

$16.07

$20.18

$20.05

25.58%

IPHA - Innate Pharma Awaits TELLOMAK Trial Data

Jun. 21

$2.56

$3.20

$1.90

25.00%

ANGO - AngioDynamics Delivers Strong Q4 Results; Provides Upbeat Sales Outlook

Jul. 12

$19.84

$24.74

$12.28

24.70%

COLL - Will 2023 Be A Banner Year For Collegium Pharma?

Nov. 7

$18.74

$23.27

$22.75

24.17%

BGNE - BeiGene: What's Making News?

Jun. 24

$169.53

$210.51

$205.00

24.17%

VLON - Vallon Pharma Flunks Pivotal ADHD Trial; Stock Plunges

Mar. 21

$2.16

$2.68

$0.30

24.07%

APLS - Premarket Mover: Apellis To Face FDA In November

Jul. 19

$56.42

$70.00

$53.00

24.07%

EXEL - Exelixis Gains On Better-than-expected Quarterly Results

Feb. 18

$18.87

$23.40

$15.94

24.01%

AUTL - Will 2022 Be A Transformational Year For Autolus?

Mar. 9

$3.82

$4.73

$1.76

23.82%

MDXG - MiMedx - Expanding Placental Portfolio

Aug. 3

$3.57

$4.42

$2.95

23.81%

NAUT - What's Making News At Nautilus Biotech?

Apr. 21

$4.10

$5.07

$1.55

23.66%

ALEC - Alector - Pioneering Immuno-neurology

Jul. 5

$10.93

$13.50

$9.07

23.51%

JANX - Janux Therapeutics - Transitions Into Clinical Stage

Oct. 20

$15.44

$19.05

$12.45

23.38%

DVAX - Dynavax Technologies - On Track For A Second Consecutive Year Of Profitability

Jul. 13

$14.17

$17.48

$11.17

23.36%

SLS - SELLAS Life To Report Ovarian Cancer Trial Data In Mid-2022

Mar. 17

$6.00

$7.40

$2.35

23.33%

LEGN - Can Legend Carve Out A Niche For Carvykti?

Oct. 24

$45.72

$56.25

$50.95

23.03%

AGTI - Agiliti Expects 12% To 14% Revenue Growth In 2022

May. 18

$18.36

$22.53

$16.85

22.71%

MDRX - Allscripts Healthcare Rises As Prel. Q4 Revenue Better Than View, On Share Buyback

Jan. 25

$19.00

$23.25

$17.78

22.37%

BBIO - A Walk Through BridgeBio

Jul. 8

$10.34

$12.64

$9.26

22.24%

EXAI - Exscientia Soars On $5.2Bln Deal With Sanofi

Jan. 7

$20.24

$24.74

$4.51

22.23%

OSUR - OraSure - Growth For Sure?

Nov. 10

$4.47

$5.46

$5.01

22.15%

ARQT - Arcutis Biotherapeutics: One Down, Four To Go

Jun. 24

$22.44

$27.40

$15.96

22.10%

IMGN - ImmunoGen To Report Q2 Results On July 29

Jul. 15

$5.43

$6.63

$5.00

22.10%

MMSI - This Stock Merits Attention

Oct. 27

$62.71

$76.14

$71.26

21.42%

AXGN - AxoGen Foresees Double-digit Revenue Growth In 2022

Sep. 16

$11.29

$13.66

$10.54

20.99%

HSTM - Will HealthStream's Q2 Results Trump Estimates?

Jul. 15

$22.02

$26.62

$24.58

20.89%

RVMD - Revolution Medicines - Focusing On RAS-targeted Cancer Therapies

Nov. 25

$21.48

$25.72

$24.30

19.74%

CPRX - Catalyst Pharma Stock Hits All-time High

Sep. 9

$15.38

$18.39

$16.00

19.57%

BVS - Will Bioventus Walk The Talk?

Feb. 28

$12.63

$15.10

$2.66

19.56%

HRMY - Will Harmony Biosciences' Q3 Results Beat Estimates?

Oct. 28

$52.09

$62.09

$55.68

19.20%

FNA - Paragon 28 Sees 16%-19% Revenue Growth In FY22

Jul. 6

$17.75

$21.15

$20.14

19.15%

ADPT - Adaptive Biotechnologies - On Path To Profitability?

Nov. 4

$8.29

$9.87

$8.01

19.06%

CASI - CASI Pharma - It's Not All About Evomela

Aug. 30

$4.10

$4.86

$1.78

18.54%

PPBT - Purple Biotech Recouping Some Of Yesterday's Losses?

Apr. 12

$3.00

$3.55

$1.59

18.33%

FNCH - Finch Therapeutics Through The PRISM…

Aug. 24

$2.45

$2.89

$0.69

17.96%

EIGR - Eiger BioPharma Awaits TOGETHER Trial Data Later This Month

Mar. 14

$8.54

$10.02

$1.12

17.33%

ANIK - Anika To Report Q3 Results On Nov.8

Oct. 28

$27.74

$32.51

$29.09

17.20%

CERT - Certara Expects FY22 Revenue To Grow Nearly 22% To 26%

Jun. 30

$21.09

$24.66

$16.17

16.93%

MYNZ - Mainz Biomed Up Over 12%; Here's Why...

Feb. 23

$15.25

$17.81

$7.08

16.79%

MEDP - Medpace - At A Steady Pace

Oct. 25

$202.45

$235.72

$206.00

16.43%

MASI - Ardelyx' Chronic Kidney Disease Drug Scores Positive Recommendation From FDA Panel

Nov. 17

$129.91

$150.87

$142.59

16.13%

PHAT - Will Phathom Pharma's Vonoprazan Cross FDA Finish Line?

Feb. 10

$17.19

$19.95

$10.79

16.06%

ITCI - Intra-Cellular Therapies' Caplyta Sees Encouraging Uptake Trends

May. 11

$52.65

$61.00

$51.05

15.86%

SNDX - Revisiting Syndax...

Sep. 20

$22.97

$26.51

$24.42

15.41%

AZYO - Aziyo Biologics Hits New High, What Next?

Oct. 25

$7.82

$9.01

$3.64

15.22%

CGEN - Compugen To Present At The American Association For Cancer Research In April

Mar. 9

$3.10

$3.57

$0.81

15.16%

DMTK - Will DermTech Regain Its Lost Sheen?

Jul. 21

$7.76

$8.93

$2.05

15.08%

LHDX - Lucira Expects Q4 Revenue To Grow Nearly Fourfold Sequentially

Feb. 9

$4.95

$5.67

$0.21

14.55%

EIGR - Eiger Beckons Investors

Jul. 14

$8.64

$9.89

$1.12

14.47%

CDXC - Will ChromaDex Walk The Talk?

Mar. 8

$2.62

$2.99

$1.50

14.12%

CALT - Calliditas Announces Commercial Launch Of Kidney Disease Drug In The U.S.

Jan. 28

$20.36

$23.01

$19.00

13.02%

PDCO - Patterson Boosts EPS Outlook On Continued Strong Momentum

Mar. 4

$31.38

$35.29

$27.53

12.46%

AIRS - Will Q4 Results Help AirSculpt Technologies Get Back In Shape?

Mar. 10

$13.00

$14.60

$3.15

12.31%

TIL - Instil Bio - On Track

Aug. 12

$6.87

$7.71

$0.58

12.23%

BTTX - Are Better Days Ahead For BTTX?

Jul. 28

$2.50

$2.80

$1.49

12.00%

ISO - Here's Why You Need To Watch IsoPlexis

Jul. 22

$3.43

$3.84

$0.71

11.95%

CAPR - Capricor's Cell Therapy - A New Hope For Duchenne Muscular Dystrophy Patients?

Sep. 30

$5.88

$6.58

$3.75

11.90%

CVAC - CureVac Rises On Preclinical Study Data Of Bivalent Second-Generation MRNA Vaccine Candidate

Apr. 21

$18.03

$20.06

$6.81

11.26%

CUTR - This Key Player In Medical Aesthetics Market Sees 10-12% Revenue Growth In FY22

Dec. 1

$47.69

$52.89

$45.57

10.90%

ACIU - AC Immune Awaits 4 Data Readouts

Jul. 13

$3.30

$3.65

$1.94

10.61%

CSII - Can The Quarterly Results Lift Cardiovascular Systems' Share Price?

Nov. 1

$14.60

$16.11

$14.51

10.34%

EGRX - Will The Recent Product Launches Add Wings To Eagle Pharma?

Feb. 23

$48.88

$53.78

$29.33

10.02%

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Business News

Global Economics Weekly Update -May 18 – May 22, 2026

May 22, 2026 14:46 ET
Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.

RELATED NEWS
Latest Updates on COVID-19